XRAY

Business Context and Reporting Period

Company: DENTSPLY International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2000
Business Overview: The Company manufactures and markets dental products, including artificial teeth, laboratory consumables, ultrasonic equipment, and infection control products. The reporting period covers the third quarter and the first nine months of fiscal year 2000.

Key Financial Metrics

Liquidity and Debt (as of Sept 30, 2000):

• Cash and Cash Equivalents: $8.2 million
• Working Capital: $130.6 million (Current Ratio: 1.7)
• Long-Term Debt: $112.9 million (Decreased $32.4 million from year-end 1999)
• Debt to Total Capitalization: 19.0%

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 5.7% in Q3 and 6.9% for the nine-month period. Base business sales (excluding acquisitions and currency) grew 8.7% in Q3 and 9.9% for the nine months.
• Currency Impact: A strengthening U.S. dollar negatively impacted sales by 3.1% in Q3 and 2.9% for the nine months, particularly in Europe.
• Profitability: Net income rose 12.8% in Q3 and 14.2% for the nine months, driven by higher sales, improved gross margins, lower interest expense, and a reduced effective tax rate (32.9% in Q3 vs. 34.8% in 1999).
• Acquisitions: The Company completed four acquisitions in 2000 (Midwest Orthodontic, Darway Inc., San Diego Swiss Machining, and a 51% interest in ESP, LLC) totaling approximately $11.65 million in cash transactions.
• Share Repurchases: The Company repurchased 1.4 million shares for $38.4 million during the first nine months of 2000.

Outlook, Risks, and Contingencies

Management Commentary:

• Management expects to finance future requirements (capex, debt service, acquisitions) through operating cash flows and existing credit facilities.
• Legal expenses increased by $4.0 million in the first nine months, primarily due to antitrust litigation with the Department of Justice and patent defense.
• SG&A expenses are expected to remain elevated due to expanded sales forces and marketing initiatives.

• Antitrust Litigation: The U.S. Department of Justice filed a complaint in 1999 alleging violations of antitrust laws regarding the distribution of artificial teeth. Private class actions are pending. The Company believes these will not have a material adverse effect.
• Contingent Consideration: An earn-out payment related to the 1996 Tulsa Dental Products acquisition is estimated at $70–80 million. If triggered, this would negatively impact net income by approximately $5.7 million annually due to goodwill amortization and borrowing costs.
• Accounting Standards: Adoption of FASB 133 (Derivatives) is required by Jan 1, 2001, expected to increase noncurrent assets by $1.7 million and other comprehensive income by $1.0 million.

• Agreement in principle to acquire Pro-Dex, Inc. for approximately $30 million in stock, expected to close in Q1 2001.

Investor Verification Checklist

• Antitrust Exposure: Verify the status of the DOJ complaint and private class actions regarding the Trubyte Division to assess potential liability.
• Tulsa Dental Earn-Out: Monitor the performance of the Tulsa Dental business to determine if the $70–80 million contingent payment will be triggered.
• Currency Hedging: Review the effectiveness of the Company's hedging strategies given the significant negative impact of the strong U.S. dollar on European sales.
• Pro-Dex Acquisition: Confirm the closing of the Pro-Dex acquisition and the final valuation terms.
• Legal Costs: Track future legal expense trends related to the antitrust and patent litigation.